~~<i id='4D682FEE9C'><strike id='4D682FEE9C'><tt id='4D682FEE9C'><pre id='4D682FEE9C'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

Wikipedia

author：fashion 2025-09-05 15:43:27 - browse：287

The FDA building -- First Opinion coverage from STAT — Adobe

WASHINGTON — The Food and Drug Administration’s top cancer drug regulator doesn’t always ask for permission before taking on big initiatives.

Richard Pazdur, director of the FDA Oncology Center of Excellence, hates bureaucracy. It stifles his ideas for getting treatments to cancer patients faster — of which there are many.

To cut through that bureaucracy, Pazdur has a trick: “Don’t tell anybody,” he said to laughter at a meeting of the advocacy group Friends of Cancer Research Tuesday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Gene therapy’s promise and the high cost of hope

entertainment

leisure time

focus

knowledge

NewresearchledbyStanfordneuro-oncologistMichelleMonjeshineslightontheelectrochemicalsignalingpathway

WSS

Merck to acquire Harpoon Therapeutics for $680 million

Travis Kelce and the trap of celebrity vaccine endorsements

Key Senate panel to consider PBM, drug pricing reform package

What is microchimerism and how does it affect maternal health?

Life sciences investors close nearly $6 billion in new funds

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

Wikipedia

Wikipedia

entertainment

Hollywood unions extend contract negotiations for actors

JPM pitch from hospitals? Revenue streams outside of patient care

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Male doctors called my cancer incurable. A female doctor showed it wasn't

Psychedelics group wrestles with new pharma identity

Life science postdocs should get big pay hike, NIH panel says

Medicare details structure of new drug price negotiation program

Explaining an after

Moonlake's readout produced a cash windfall. Risks remain

JPM pitch from hospitals? Revenue streams outside of patient care

entertainment

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

Merck to acquire Harpoon Therapeutics for $680 million

Medicare must police algorithms in Medicare Advantage, Dems say

Physician assistants need a new name. Here's what it should be

Brain injuries and the importance of a second opinion

leisure time

focus

knowledge

knowledge